Boehringer Ingelheim GmbH, of Ingelheim, Germany, said results from a phase II study published in Blood showed that patients with previously untreated acute myeloid leukemia (AML), ages 65 and older and ineligible for intensive remission induction therapy, lived longer when treated with volasertib combined with low-dose cytarabine (LDAC) vs. LDAC alone.